BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 – 13. EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardia
Click here to view original post
News
As Car Thefts Rise, CU Anschutz Police Department and Campus Partners Provide Safety Tips, Debut New Program
Colorado leads the nation in auto theft and, unfortunately, Denver and Aurora are two of the prime targets for thieves. On campus thus far in 2022 we have recorded reports of 106 stolen vehicles and […]
News
Medline deploys new AutoStore installation at distribution center in Aurora, Colorado
NORTHFIELD Ill., May 18, 2026 /PRNewswire/ — Medline (Nasdaq: MDLN) has unveiled a new AutoStore™ installation at its distribution center in Aurora, Colo., as part of an ongoing effort to drive efficiency, optimize fulfillment and […]
News
STRIDETECH GO COMPATIBLE WITH WALKERS MADE BY MEDLINE, DRIVE, NOVA, VIVE, U-STEP, AND MORE
BOULDER, Colo. , June 14, 2022 /PRNewswire/ — Stride Tech Medical, Inc., www.stridetechgo.com (StrideTech) announces results of testing StrideTech GO on walkers. STRIDETECH GO COMPATIBLE WITH WALKERS MADE BY MEDLINE, DRIVE, NOVA, VIVE, U-STEP, AND […]
